News & Updates
Filter by Specialty:
T2D, orthostatic hypotension up risks of falls, in-hospital mortality
The risk of falls is higher among sedentary patients and those with lower Timed Up and Go test (TUG), according to a study. Patients with type 2 diabetes (T2D) are also at increased risk of falls.
T2D, orthostatic hypotension up risks of falls, in-hospital mortality
12 Feb 2023
Genital tract infections not a risk factor for cytologic abnormalities regardless of HPV infection status
Neither vulvovaginal candidiasis nor bacterial vaginosis is associated with increased incidence of cervical cytologic abnormalities among women with or without human papillomavirus (HPV) infection, according to a study. Bacterial vaginosis may even have a protective effect against cytologic abnormalities among women with HPV coinfection.
Genital tract infections not a risk factor for cytologic abnormalities regardless of HPV infection status
11 Feb 2023
Metformin lowers HCC risk after antiviral therapy in diabetic patients with hepatitis C
Treatment with metformin results in a significant reduction in hepatocellular carcinoma (HCC) incidence following successful antiviral therapy in individuals with diabetes mellitus and chronic hepatitis C (CHC), a recent study has shown.
Metformin lowers HCC risk after antiviral therapy in diabetic patients with hepatitis C
11 Feb 2023
Novel KRAS G12C inhibitor shows promising antitumour activity in mutated pancreatic cancer
The investigational KRAS G12C inhibitor sotorasib appears to be active against previously treated KRAS p.G12C–mutated advanced pancreatic cancer while having an acceptable safety profile, according to the results of a phase I/II trial.
Novel KRAS G12C inhibitor shows promising antitumour activity in mutated pancreatic cancer
11 Feb 2023
Is first-line lazertinib monotherapy a potential new SoC for EGFRm NSCLC?
Patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) exhibited significantly improved progression-free survival (PFS) when treated with lazertinib compared with gefitinib in the first-line setting, results of the LASER301 trial showed.